Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sipuleucel-T in metastatic castrate resistant prostate cancer
NCT00901342Phase 2Completed
- Sponsor
- Dendreon
- Start
- Oct 2009
- Primary completion
- Dec 2014
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Dendreon. Started Oct 2009; status: completed.
02
Drugs
sipuleucel-T
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00901342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00901342.